A detailed history of Captrust Financial Advisors transactions in Seres Therapeutics, Inc. stock. As of the latest transaction made, Captrust Financial Advisors holds 13,100 shares of MCRB stock, worth $12,576. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,100
Holding current value
$12,576
% of portfolio
0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$0.7 - $1.48 $9,170 - $19,388
13,100 New
13,100 $12,000
Q1 2022

May 16, 2022

SELL
$6.3 - $8.84 $1,417 - $1,989
-225 Reduced 69.02%
101 $1,000
Q4 2021

Feb 14, 2022

BUY
$6.02 - $11.43 $608 - $1,154
101 Added 44.89%
326 $3,000
Q3 2021

Nov 16, 2021

SELL
$5.46 - $22.6 $1,588 - $6,576
-291 Reduced 56.4%
225 $2,000
Q2 2021

Aug 16, 2021

BUY
$18.46 - $24.36 $6,405 - $8,452
347 Added 205.33%
516 $12,000
Q1 2021

May 17, 2021

BUY
$17.66 - $28.92 $2,984 - $4,887
169 New
169 $3,000

Others Institutions Holding MCRB

About Seres Therapeutics, Inc.


  • Ticker MCRB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 124,072,000
  • Market Cap $119M
  • Description
  • Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the ...
More about MCRB
Track This Portfolio

Track Captrust Financial Advisors Portfolio

Follow Captrust Financial Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Captrust Financial Advisors with notifications on news.